Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Compounding | 14 | 2024 | 76 | 5.750 |
Why?
|
| Chromones | 9 | 2023 | 54 | 5.440 |
Why?
|
| Drug Stability | 15 | 2024 | 116 | 4.920 |
Why?
|
| Suspensions | 14 | 2024 | 46 | 4.060 |
Why?
|
| Administration, Oral | 11 | 2024 | 224 | 2.090 |
Why?
|
| Chromatography, High Pressure Liquid | 12 | 2024 | 421 | 1.820 |
Why?
|
| Allopurinol | 2 | 2024 | 12 | 1.720 |
Why?
|
| Naltrexone | 2 | 2024 | 38 | 1.630 |
Why?
|
| Clindamycin | 2 | 2024 | 13 | 1.540 |
Why?
|
| Drug Storage | 7 | 2023 | 27 | 1.320 |
Why?
|
| Bethanechol | 1 | 2024 | 4 | 0.980 |
Why?
|
| Clonidine | 1 | 2024 | 52 | 0.960 |
Why?
|
| Azathioprine | 1 | 2023 | 5 | 0.910 |
Why?
|
| Pyrimethamine | 1 | 2023 | 10 | 0.890 |
Why?
|
| Amitriptyline | 1 | 2022 | 9 | 0.860 |
Why?
|
| Spironolactone | 2 | 2024 | 39 | 0.810 |
Why?
|
| Metronidazole | 1 | 2021 | 13 | 0.780 |
Why?
|
| Hydrocortisone | 1 | 2021 | 78 | 0.760 |
Why?
|
| Uric Acid | 1 | 2020 | 26 | 0.740 |
Why?
|
| Amlodipine | 1 | 2019 | 21 | 0.700 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 5 | 0.670 |
Why?
|
| Sulfadiazine | 1 | 2017 | 4 | 0.610 |
Why?
|
| Trimethoprim | 1 | 2017 | 6 | 0.610 |
Why?
|
| Excipients | 3 | 2023 | 22 | 0.570 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 284 | 0.570 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 352 | 0.450 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2017 | 364 | 0.400 |
Why?
|
| Humans | 11 | 2023 | 37093 | 0.340 |
Why?
|
| Child | 3 | 2021 | 3131 | 0.320 |
Why?
|
| Viscosity | 2 | 2017 | 38 | 0.300 |
Why?
|
| Tablets | 1 | 2024 | 9 | 0.250 |
Why?
|
| Nanoparticles | 3 | 2015 | 318 | 0.240 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 409 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2017 | 98 | 0.150 |
Why?
|
| Liposomes | 3 | 2011 | 118 | 0.130 |
Why?
|
| Squalene | 1 | 2015 | 3 | 0.130 |
Why?
|
| Mebendazole | 1 | 2015 | 4 | 0.130 |
Why?
|
| Tubulin Modulators | 1 | 2015 | 18 | 0.130 |
Why?
|
| Temperature | 1 | 2016 | 286 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2015 | 127 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2015 | 125 | 0.120 |
Why?
|
| Artemisinins | 1 | 2014 | 20 | 0.120 |
Why?
|
| Antimalarials | 1 | 2014 | 55 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 132 | 0.110 |
Why?
|
| Lipids | 2 | 2011 | 235 | 0.100 |
Why?
|
| Freeze Drying | 1 | 2011 | 27 | 0.100 |
Why?
|
| RNA Stability | 1 | 2011 | 26 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2011 | 151 | 0.090 |
Why?
|
| Nanocapsules | 1 | 2010 | 17 | 0.090 |
Why?
|
| RNA Interference | 1 | 2011 | 243 | 0.090 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2010 | 71 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2010 | 158 | 0.090 |
Why?
|
| Aged | 1 | 2021 | 6741 | 0.080 |
Why?
|
| Liver | 1 | 2011 | 479 | 0.080 |
Why?
|
| Adolescent | 1 | 2019 | 5363 | 0.080 |
Why?
|
| DNA | 1 | 2010 | 574 | 0.070 |
Why?
|
| Particle Size | 2 | 2015 | 215 | 0.050 |
Why?
|
| Hepacivirus | 2 | 2011 | 62 | 0.050 |
Why?
|
| Protamines | 2 | 2011 | 18 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 2231 | 0.050 |
Why?
|
| Transfection | 2 | 2011 | 523 | 0.040 |
Why?
|
| Poloxamer | 1 | 2015 | 9 | 0.030 |
Why?
|
| Transition Temperature | 1 | 2015 | 8 | 0.030 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2015 | 30 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 142 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 56 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 59 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 118 | 0.030 |
Why?
|
| Sonication | 1 | 2011 | 16 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2011 | 20 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2011 | 34 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2011 | 43 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 63 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2011 | 75 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 142 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 146 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 935 | 0.020 |
Why?
|
| Pressure | 1 | 2010 | 43 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 47 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2011 | 125 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 205 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2011 | 153 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2011 | 157 | 0.020 |
Why?
|
| Plasmids | 1 | 2010 | 246 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 278 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 864 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 1742 | 0.020 |
Why?
|
| Mice | 1 | 2010 | 5913 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 15081 | 0.010 |
Why?
|